Clinical Investigation on Safety, Feasibility and Usability of the ABLE Exoskeleton Device With Spinal Cord Injured Patients in a Hospital Setting

NCT ID: NCT04876794

Last Updated: 2022-01-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-03
• Study Completion Date: 2021-11-19

Brief Summary

The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians. Exoskeletal technology has the potential to help people with impaired leg function to regain ambulation and thus improve their independence. This technology is not completely new, but due to their high access price (~120k€/unit), high size and weight (~25 kg), and need for trained physiotherapist supervision, commercially available exoskeletons are only found in large hospitals and only in very few cases get into patients' homes.

The company ABLE Human Motion S.L. (Barcelona, Spain) has developed a novel exoskeleton to overcome these disadvantages, which is more compact, lighter (9 kg) and easier to use.

The primary objective of the study is to investigate the safety, feasibility and usability of the ABLE exoskeleton device in people with spinal cord injury during a four to six weeks gait training in clinical settings. Furthermore, potential effects of the training on walking, general health status, user satisfaction, and quality of life will be assessed.

Detailed Description

The primary objective of this study is to determine the safety, feasibility, and usability of using the ABLE Exoskeleton for patients with SCI in a hospital setting during a 4-6 week training programme.

The secondary objectives are as follows:

• Assess the impact of ABLE Exoskeleton training on gait and function.
• Assess the effect on the perceived rate of exertion for patients using the ABLE Exoskeleton.
• Assess the level of user satisfaction from participants and therapists of the ABLE Exoskeleton.
• Assess the psychosocial impact of the ABLE Exoskeleton for participants

Patients who match inclusion and exclusion criteria and pass pre-study screening will be enrolled in the study. Following the screening, baseline assessments will be conducted without the device. Participants will undergo a training programme with the ABLE Exoskeleton three times a week for four weeks for a total of 12 sessions. Standardized clinical assessments with the device will be performed during the first and the last training sessions. During the training period, several safety and usability measurements will be taken. After the last training session, baseline assessments without the exoskeleton will be repeated during a post-study assessment. Four weeks after the final training session a follow-up assessment will be conducted with participants. At the end of the study, the participating therapists will be asked to fill out a satisfaction questionnaire.

This is the first study investigating the use of the ABLE Exoskeleton, therefore the primary hypothesis of this study is that the ABLE Exoskeleton is safe, feasible, and usable for the intended patient population with SCI in a hospital setting. The secondary hypothesis is that the device will have a positive impact on the perceived rate of exertion, mobility, and psychosocial health of the study participants with SCI.

Conditions

Spinal Cord Injuries

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1

Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.

Group Type: EXPERIMENTAL

ABLE Exoskeleton

Intervention Type: DEVICE

Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.

Interventions

ABLE Exoskeleton

Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 18 to 70 years of age
• Traumatic and non-traumatic SCI
• Currently receiving treatment as an inpatient or outpatient at one of the investigational sites
• AIS A to AIS D with sufficient arm strength to support body weight on a walking frame
• Ability to give informed consent

Exclusion Criteria

• WISCI II without exoskeleton of >16
• 5 or more risk factors for fragility as stated by Craven et al (29)
• History of lower limb fragility fractures in the last 2 years
• Deterioration > 3 points of the total International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor score within the last 4 weeks
• Spinal instability
• Modified Ashworth scale (MAS) > 3 in lower limbs
• Unable to tolerate 30 min standing without clinical symptoms of orthostatic hypotension
• Unable to perform a sit-to-stand transfer or stand in the device with assistance
• Psychological or cognitive issues that do not allow a participant to follow the study procedures
• Any neurological condition other than SCI
• Medically unstable
• Severe comorbidities including any condition that a physician considers to not be appropriate to complete participation in the study
• Ongoing skin issues
• Height, width, weight or other anatomical constraints (such as leg length differences) incompatible with the device
• Insufficient Range of Motion (ROM) for ABLE Exoskeleton device
• Known pregnancy or breastfeeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institut Guttmann

OTHER

Sponsor Role: collaborator

Heidelberg University Hospital Spinal Cord Injury Center

UNKNOWN

Sponsor Role: collaborator

ABLE Human Motion S.L.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rüdiger Rupp, PD Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital Heidelberg

Locations

Spinal Cord Injury Center | Heidelberg University Hospital

Heidelberg, , Germany

Institut Guttmann

Badalona, Barcelona, Spain

Countries

Germany; Spain

Other Identifiers

CIV-20-07-034264

Identifier Type: REGISTRY

Identifier Source: secondary_id

ABLEexoSCIhospital

Identifier Type: -

Identifier Source: org_study_id